ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal ant...
Q1 2026
May 7, 2026
FY 2025
Mar 10, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Jul 24, 2025
